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Rationale: Oral corticosteroid (OCS) dependence is prevalent in severe asthma and causes 
adverse effects, including adrenal insufficiency (AI). Benralizumab may reduce or eliminate the 
need for long-term OCS for adults with severe asthma. AI may be perceived as a barrier to OCS 
reduction, and limited data are available to guide the extent to which OCS can be tapered in the 
presence of AI.  
Methods: An analysis of patients in the multicenter, open-label phase IIIb PONENTE trial was 
conducted to demonstrate benralizumab’s ability to eliminate or reduce the daily OCS dosage 
according to adrenal function status. Hypothalamic-pituitary-adrenal (HPA) axis integrity was 
evaluated after patients reached a daily OCS dosage of 5 mg for 4 weeks. A morning cortisol 
level was obtained to determine if patients had normal adrenal function (>350 nmol/L) or 
complete AI (<100 nmol/L). Patients with indeterminate results (100–350 nmol/L) underwent an 
ACTH stimulation test. According to this result, patients were classified as having normal 
cortisol levels (>450 nmol/L), complete AI (<250 nmol/L), or partial AI (250–450 nmol/L). 
Adrenal status determined whether the OCS down-titration was continued (and the rate of OCS 
down-titration) or suspended (due to complete AI), and was re-evaluated 2–3 months later to 




allowed any further dosage reductions. Endpoints included OCS elimination and achieving a 
daily OCS dosage ≤5 mg. 
Results: A total of 530 of 598 eligible patients completed the initial HPA axis assessment. At 
first testing, 40% of patients had normal cortisol levels, 33% had partial AI, and 27% had 
complete AI. Overall, more than one-third of patients with initial complete or partial AI 
recovered their adrenal function 2 to 3 months later (36.2% from partial AI to normal levels and 
31.9% from complete AI to partial AI or normal levels). More than 90% of patients with normal 
adrenal function or who improved from partial AI to normal levels and more than 60% of 
patients who improved from complete AI to partial AI or normal levels eliminated OCS use. 
Nearly all patients eliminated OCS or achieved a dosage ≤5 mg, regardless of initial AI status 
(Table).  
Conclusions: Most patients with normal adrenal function eliminated OCS or achieved a daily 
OCS dosage ≤5 mg, and a substantial percentage of patients with initially impaired adrenal 










OCS, n (%) 
Patients achieving daily 
OCS dosage ≤5 mg if AI 
was the cause of stopping 
the taper, n (%) 
Patients achieving daily 
OCS dosage ≤5 mg 
regardless of the cause of 
stopping the taper, n (%) 
Adrenal function status at initial HPA axis testing (N=530) 
Normal (40.0%; N=212) 196 (92.5) 197 (92.9) 209 (98.6) 
Partial AI (33.0%; N=175) 132 (75.4) 151 (86.3) 171 (97.7) 
Complete AI (27.0%; N=143) 30 (21.0) 120 (83.9) 135 (94.4) 
Patients with improvements in adrenal function status from initial to final HPA axis testing (N=260*; 
 subset of patients with partial or complete AI at initial testing) 
Any improvement in adrenal 
function status at second HPA 
testing (34.2%; n/N=89/260) 
70 (78.7) 71 (79.8) 86 (96.6) 
Improvement from partial AI 
to normal levels  
(36.2%; n/N=51/141) 
47 (92.2) 47 (92.2) 50 (98.0) 
Improvement from complete AI 
to partial AI/normal levels 
(31.9%; n/N=38/119) 
23 (60.5) 24 (63.2) 36 (94.7) 
Patients with compromised adrenal function status at initial and final HPA axis testing (N=472*) 
Complete AI throughout 
(17.2%; n/N=81/472) 
1 (1.2) 79 (97.5) 80 (98.8) 
Partial AI throughout  
(14.4%; n/N=68/472) 
56 (82.4) 57 (83.8) 67 (98.5) 
 
AI=adrenal insufficiency; HPA=hypothalamic-pituitary-adrenal axis; OCS=oral corticosteroids. 
*58 patients with partial or complete AI (34 and 24 patients, respectively) at initial testing did not have 
adrenal function status completed at final HPA testing, leading to 141 patients with partial AI and 119 
with complete AI being tested for adrenal function status at final HPA axis testing. 58 patients did not 
have adrenal function status at final HPA axis testing.  
 
 
